Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | ARG1 | P05089 | 1/20 | 0.37 |
| ▸ | ARG2 | P78540 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 3/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | METAP1 | P53582 | 2/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4571093 | 1.00 | KIF11 (0.38) | KIF11ARG1ARG2NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL5353333 | 0.98 | KIF11 (0.37) | KIF11ARG1ARG2NOS2NOS1 | |
| SCHEMBL14614801 | 0.85 | KIF11 (0.39) | KIF11ARG1ARG2NOS2NOS1 | |
| SCHEMBL27622257 | 0.83 | KIF11 (0.38) | KIF11ARG1ARG2NOS2NOS1 | |
| SCHEMBL7538467 | 0.83 | BHMT (0.41) | KIF11ARG1ARG2NOS2NOS1 | |
| SCHEMBL22381012 | 0.83 | BHMT (0.41) | KIF11ARG1ARG2NOS2NOS1 | |
| SCHEMBL5641243 | 0.83 | KIF11 (0.38) | KIF11ARG1ARG2NOS2NOS1 | |
| SCHEMBL7538461 | 0.83 | BHMT (0.41) | KIF11ARG1ARG2NOS2NOS1 | |
| SCHEMBL23129041 | 0.79 | KIF11 (0.40) | KIF11ARG1ARG2NOS2NOS1 | |
| SCHEMBL1709969 | 0.79 | KIF11 (0.40) | KIF11ARG1ARG2NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304057-B2 | Substituted 6-membered N-heterocyclic compounds and method for their use as neurological regulator | Institute of Pharmacology and Toxicology Accademy of Military Medical Sciences P.L.A. China (CN) | 2007-12-04 | — | — | US | disclosed |
| US-20050130958-A1 | Substituted 6−membered n−heterocyclic compounds and their uses as neurological regulator | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130958-A1 | Substituted 6−membered n−heterocyclic compounds and their uses as neurological regulator | BDNF, NGF, NTRK2 | KIF11 1867/4885ARG1 2749/4885ARG2 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.